Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemiafor B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative275 locations incl. BirminghamSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT03739814·Phase 2·RecruitingApply to this trial
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgeryfor Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7140 locations incl. TucsonSponsor: ECOG-ACRIN Cancer Research GroupSex: All·Age: 18+Code: NCT03493425·Phase 2·RecruitingApply to this trial
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancerfor Castration Levels of Testosterone334 locations incl. GilbertSponsor: SWOG Cancer Research NetworkSex: Male·Age: 18+Code: NCT03678025·Phase 3·RecruitingApply to this trial
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemiafor B Acute Lymphoblastic Leukemia455 locations incl. BirminghamSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 18 - 39Code: NCT03150693·Phase 3·RecruitingApply to this trial
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgeryfor Head and Neck Squamous Cell Carcinoma676 locations incl. BirminghamSponsor: ECOG-ACRIN Cancer Research GroupSex: All·Age: 18+Code: NCT02734537·Phase 2·RecruitingApply to this trial
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomasfor Intracranial Meningioma780 locations incl. BirminghamSponsor: Alliance for Clinical Trials in OncologySex: All·Age: 18+Code: NCT02523014·Phase 2·RecruitingApply to this trial
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancerfor Oropharyngeal p16INK4a-Negative Squamous Cell CarcinomaDrug: Atezolizumab338 locations incl. BirminghamSponsor: National Cancer Institute (NCI)Sex: All·Age: 18+Code: NCT01810913·Phase 2, Phase 3·RecruitingApply to this trial